Literature DB >> 10383518

Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis.

R J Laheij1, L G Rossum, J B Jansen, H Straatman, A L Verbeek.   

Abstract

OBJECTIVE: To assess effectiveness of treatment to cure Helicobacter pylori infection. DATA SYNTHESIS: Meta-analysis of 666 manuscripts (full papers, abstracts, letters to the editor) identified through Medline and a manual search (1986 to January 1998). Data were overviewed by regression analysis with weighted random effects models.
SUBJECTS: 53 228 patients with H. pylori infection.
INTERVENTIONS: Patients were treated with 132 different medication combinations. MAIN OUTCOME MEASURE: Cure of H. pylori infection per protocol and intention-to-treat basis at least 28 days after treatment.
RESULTS: The nationality of the patients and therapeutic regimen have a significant impact on the results, after correction for the heterogeneity in the precision of the cure rate caused by different study sizes and random effect for study. On the basis of the original sample size, cure rates of 80-85% were achieved using combinations of a proton-pump inhibitor or ranitidine bismuth citrate with two antibiotics including clarithromycin, amoxycillin and metronidazole or tinidazole. Comparable cure rates were also achieved using a combination of a proton-pump inhibitor or H2-receptor antagonist with bismuth subcitrate or tripotassium dicitrato bismuthate, metronidazole and tetracycline. The dose of clarithromycin influenced cure rates. Treatment duration did not influence the outcome.
CONCLUSION: Several therapeutic regimens are eligible to cure H. pylori infection. However, none of the medication combinations were able to cure H. pylori infection in more than 85% of the patients assessed by intention-to-treat. The countries in which the studies were performed also had a significant impact on eradication rates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383518     DOI: 10.1046/j.1365-2036.1999.00542.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  40 in total

1.  First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective.

Authors:  György-Miklós Buzás
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

2.  Efficacy and tolerability of rifampicin-based rescue therapy for Helicobacter pylori eradication failure in peptic ulcer disease.

Authors:  Vineet Ahuja; Vikram Bhatia; S Dattagupta; Akshay Raizada; Mahesh Prakash Sharma
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

3.  Chemometric descriptors in modeling the carbonic anhydrase inhibition activity of sulfonamide and sulfamate derivatives.

Authors:  Brij Kishore Sharma; Pradeep Pilania; Kirti Sarbhai; Prithvi Singh; Yenamandra S Prabhakar
Journal:  Mol Divers       Date:  2009-08-06       Impact factor: 2.943

4.  Second-line and third-line trial for helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study.

Authors:  György M Buzás; Hajnalka Györffy; Ilona Széles; Anna Szentmihályi
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

5.  Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients.

Authors:  R Urgesi; G Pelecca; R Cianci; A Masini; C Zampaletta; M E Riccioni; R Faggiani
Journal:  Can J Gastroenterol       Date:  2011-06       Impact factor: 3.522

6.  Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

Review 7.  Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Macrolides: A Canadian Infectious Disease Society position paper.

Authors:  S McKenna; G Evans
Journal:  Can J Infect Dis       Date:  2001-07

9.  Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.

Authors:  Giuseppe Scaccianoce; Cesare Hassan; Alba Panarese; Donato Piglionica; Sergio Morini; Angelo Zullo
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

10.  Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study.

Authors:  Yvonne Guttner; Helen M Windsor; Charlie H Viiala; Leon Dusci; Barry J Marshall
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.